Moderna, Inc.
MRNAAPI behind this page
MRNA Q1 2026 request
Playground key active
/api/financials?ticker=MRNA&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 389 | 108 | +260.2% |
Show Product Lines breakouts |
|||
| Collaboration Arrangement, Including Arrangements With Affiliate [Member] | 5 | 1 | +400.0% |
| COVID | 345 | 84 | +310.7% |
| Net product sales | 352 | 86 | +309.3% |
| Net product sales · Europe | 239 | — | — |
| Net product sales · Rest of world | 40 | 55 | -27.3% |
| Net product sales · US | 73 | 31 | +135.5% |
| Product And Service Other | 37 | 22 | +68.2% |
| RSV | 7 | 2 | +250.0% |
| Stand-ready manufacturing revenue | 32 | 12 | +166.7% |
| Cost of Revenue | 955 | 90 | +961.1% |
| Research & Development | 649 | 856 | -24.2% |
Show Counterparty Name breakouts |
|||
| Blackstone Life Sciences (Blackstone) · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 50 | 90 | -44.4% |
| Merck · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 101 | 104 | -2.9% |
| General & Administrative | 173 | 212 | -18.4% |
| Total Costs & Expenses | 1,777 | 1,158 | +53.5% |
| Operating Income | -1,388 | -1,050 | -32.2% |
| Interest Income | 72 | 90 | -20.0% |
| Other Non-Operating Income (Expense) | -18 | -4 | -350.0% |
| Income Before Taxes | -1,334 | -964 | -38.4% |
| Income Tax Expense (Benefit) | 9 | 7 | +28.6% |
| Net Income | -1,343 | -971 | -38.3% |
Show Equity Components breakouts |
|||
| Retained Earnings | -1,343 | -971 | -38.3% |
| EPS (Basic) | -3.4 | -2.52 | -34.9% |
| EPS (Diluted) | -3.4 | -2.52 | -34.9% |
| Wtd Avg Shares (Basic) | 395 | 386 | +2.3% |
| Wtd Avg Shares (Diluted) | 395 | 386 | +2.3% |
| Comprehensive Income | -1,363 | -951 | -43.3% |
| Other Comprehensive Income | -20 | 20 | -200.0% |
Show Equity Components breakouts |
|||
| Accumulated Net Unrealized Investment Gain Loss | -17 | — | — |
| Accumulated Other Comprehensive Income | -20 | 20 | -200.0% |
| Accumulated Translation Adjustment | -3 | — | — |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,908 | 1,623 | +17.6% |
| Available For Sale Securities Debt Securities Current | 3,297 | 4,352 | -24.2% |
| Accounts Receivable | 71 | 78 | -9.0% |
| Inventory | 146 | 128 | +14.1% |
| Prepaid Expenses & Other Current Assets | 348 | 585 | -40.5% |
| Total Current Assets | 5,770 | 6,766 | -14.7% |
| Non-Current Assets | |||
| Available For Sale Securities Debt Securities Noncurrent | 2,251 | 2,418 | -6.9% |
| Operating Lease Right-of-Use Assets | 706 | 752 | -6.1% |
| Other Non-Current Assets | 675 | 556 | +21.4% |
| Total Assets | 11,488 | 12,704 | -9.6% |
| Goodwill | 52 | 52 | 0.0% |
| Intangible Assets | 116 | — | — |
Show Litigation Case breakouts |
|||
| Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) · Intellectual Property | 72 | — | — |
| Deferred Tax Assets | 82 | 81 | +1.2% |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 2,086 | — | — |
| Current Liabilities | |||
| Accounts Payable | 161 | 226 | -28.8% |
| Accrued Liabilities | 1,912 | 1,001 | +91.0% |
| Deferred Revenue (Current) | 102 | 125 | -18.4% |
| Other Liabilities Current | 220 | 252 | -12.7% |
| Total Current Liabilities | 2,395 | 1,604 | +49.3% |
| Non-Current Liabilities | |||
| Contract With Customer Liability Noncurrent | 154 | 58 | +165.5% |
| Operating Lease Liabilities | 645 | 667 | -3.3% |
| Finance Lease Liability Noncurrent | 13 | 35 | -62.9% |
| Long-Term Debt | 590 | — | — |
| Other Non-Current Liabilities | 283 | 274 | +3.3% |
| Total Liabilities | 4,080 | 2,638 | +54.7% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| Initial Term Loan · Secured Debt | 590 | — | — |
| Deferred Tax Liabilities | 253 | 234 | +8.1% |
| Stockholders' Equity | |||
| Additional Paid-In Capital | 1,503 | 982 | +53.1% |
| Accumulated Other Comprehensive Income | 25 | 10 | +150.0% |
| Retained Earnings | 5,880 | 9,074 | -35.2% |
| Total Stockholders' Equity | 7,408 | 10,066 | -26.4% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 4 | -10 | +140.0% |
| Accumulated Net Unrealized Investment Gain Loss | 21 | 25 | -16.0% |
| Accumulated Other Comprehensive Income | 25 | 10 | +150.0% |
| Additional Paid In Capital | 1,503 | 982 | +53.1% |
| Retained Earnings | 5,880 | 9,074 | -35.2% |
| Total Liabilities & Equity | 11,488 | 12,704 | -9.6% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 104 | 115 | -9.6% |
| Other Depreciation And Amortization | 59 | 39 | +51.3% |
| Investment Income Net Amortization Of Discount And Premium | -11 | -19 | +42.1% |
| Income Loss From Equity Method Investments Net Of Dividends Or Distributions | 2 | 8 | -75.0% |
| Other Non-Cash Items | 6 | 2 | +200.0% |
| Change in Accounts Receivable | 114 | 280 | -59.3% |
| Change in Prepaid & Other Assets | 54 | 46 | +17.4% |
| Change in Inventory | 6 | -8 | +175.0% |
| Increase Decrease In Right Of Use Asset Operating Leases | 11 | 9 | +22.2% |
| Change in Accounts Payable | -120 | -156 | +23.1% |
| Increase Decrease In Accrued Liabilities | 464 | -381 | +221.8% |
| Change in Deferred Revenue | 5 | -29 | +117.2% |
| Increase Decrease In Operating Lease Liability | -7 | -5 | -40.0% |
| Increase Decrease In Other Operating Liabilities | 26 | 33 | -21.2% |
| Net Cash from Operations | -630 | -1,037 | +39.2% |
| Depreciation & Amortization | 56 | 38 | +47.4% |
| Investing Activities | |||
| Purchases of Investments | -1,348 | -1,764 | +23.6% |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 732 | 1,933 | -62.1% |
| Proceeds From Sale Of Available For Sale Securities Debt | 602 | 688 | -12.5% |
| Capital Expenditures | -62 | -117 | +47.0% |
| Net Cash from Investing | -76 | 730 | -110.4% |
| Intangible Asset Expenditures Incurred But Not Yet Paid | 74 | — | — |
| Financing Activities | |||
| Proceeds From Stock Plans | 19 | 3 | +533.3% |
| Tax Withholding for Share Compensation | -2 | -1 | -100.0% |
| Net Cash from Financing | 17 | 4 | +325.0% |
| Supplemental | |||
| Unpaid Capital Expenditures | 35 | 50 | -30.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1 | — | — |
| Net Change in Cash | -688 | -303 | -127.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,909 | 1,626 | +17.4% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.